P/B
3
Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
$3.7B
Market Cap • 9/25/2026
2015
(11 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
2,9
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
6,6
EPS
—
Market Cap
Market Cap
3,7B
EV
2,9B
EV/Revenue
2,2
EV/EBITDA
-51,8
EV/EBIT
-51,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Profitability
Gross Margin
56,6%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
31,2%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
25,6%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
71,5%
CAGR Op. Income 5Y
-29,1%
CAGR Net Income 5Y
-21,4%
CAGR EPS 5Y
-26,2%
CAGR OCF 5Y
-15,3%
Leverage
N.D./EBITDA
15,3
Debt/Equity
0%
Current Ratio
3
Quick Ratio
2,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!